Skip to main content
françaisFR
European Commission logo print header

Optimal treatment for patients with solid tumours in Europe through Artificial intelligence

Description du projet

DEENESFRITPL

Améliorer le traitement des patients atteints de cancers du poumon, du sein ou de la prostate

Le nombre de cas de cancer en Europe devrait augmenter de 14 % d’ici 2030. Chez les patients, cela entraîne une demande croissante de traitements innovants contre le cancer. Dans ce contexte, le projet OPTIMA, financé par l’UE, réunira la Société Européenne de Pneumologie et la European Lung Foundation, ainsi que 34 autres partenaires. L’objectif consiste à concevoir, à développer et à fournir la première plateforme européenne de génération de preuves et de données oncologiques réelles interopérable, ainsi que des ensembles d’outils d’aide à la prise de décision pour les cancers du sein, du poumon et de la prostate. OPTIMA établira des procédures de bonnes pratiques pour l’intégration d’analyses et de preuves éclairées par des technologies et des outils d’intelligence artificielle.

Objectif

OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individualised treatments and to innovative therapies. In that perspective, we will design, develop and deliver the first interoperable and GDPR compliant European real-world oncology data and evidence generation platform, along with decision support toolsets for prostate, lung and breast cancer. By designing this platform from the onset based on the needs of the clinicians and patients in an inclusive and sustainable way, OPTIMA aims to strengthen shared decision-making based on innovative data and AI-driven technology and tools.

To achieve our vision, we have united the key partners from other data-driven European wide oncology initiatives (PIONEER, EHDEN, HARMONY) in our project along with Europes leading clinicians in the fields of breast, prostate and lung cancer that all have leading roles in medical societies such as ERS, ESMO, and EAU. At the core of the OPTIMA project are the major guideline offices of the three indications, whilst the project is further strengthened by patient advocacy groups, well-known academic partners and 6 SMEs as partners covering the needed expertise to implement OPTIMA successfully.

The platform will build on existing open source solutions such as the OMOP-CDM, tranSMART and OHDSI ATLAS whilst developing novel AI models based on federated learning to facilitate knowledge discovery. At the start of the project, we will already have access to datasets covering over 200M people in Europe, along with data from high quality patient cohorts for AI model building. Moreover, the platform will be hosted in-kind on existing infrastructure provided by Helmholtz Institute in Germany. Finally, OPTIMA envisions sustainability of its platform through a value-based approach with various business models for commercial users.

Champ scientifique

Mots‑clés

Programme(s)

Thème(s)

Appel à propositions

H2020-JTI-IMI2-2020-23-two-stage

Voir d’autres projets de cet appel

Régime de financement

RIA - Research and Innovation action

Coordinateur

STICHTING EUROPEAN UROLOGICAL FOUNDATION
Contribution nette de l'UE
€ 822 280,00
Adresse
Mr. e.n. van kleffenstraat 5
6842 CV Arnhem
Pays-Bas

Voir sur la carte
PME

L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
Oui
Région
Oost-Nederland Gelderland Arnhem/Nijmegen
Type d’activité
Other
Liens
Autres sources de financement
€ 1 978 000,00

Participants (39)

Partager cette page

Télécharger

Dernière mise à jour: 24 Novembre 2023

Mon livret

Permalink: https://cordis.europa.eu/project/id/101034347/fr

European Union, 2023